Open original FDA record ↗Recall record
- FDA identifier
- Z-0749-2022
- Company in FDA record
- Abbott Laboratories, Inc
- FDA record creation date
- Mar 11, 2022
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Software error associated with the immunoassay analyzer wash cycle which is using 1 mL of wash buffer instead of the intended 3 mL of wash buffer to wash the exterior of the probe.
Source facts
- Action
- On February 3, 2022, Abbott issued two "Urgent Product Correction" notifications. For US customers these notification where delivered by Abbott personnel. For OUS consignees letters were provided by Abbott personnel or by email. During the week of February 25, 2022, an updated letter was provided to US customers containing additional information. In addition to informing consignees about the recall the firm provided the following instructions Please perform the necessary immediate actions, if utilizing the Alinity s HIV Ag/Ab Combo and Alinity s Anti-HCV II assays while operating on Alinity s System SW version 2.8.0, to continue to use the Alinity s System. These actions mitigate potential impact for false reactive results when using the Alinity s HIV Ag/Ab Combo Reagent kit. The Alinity s HIV Ag/Ab Combo and Alinity s Anti-HCV II assays are not installed or do not run on the same Alinity s System. - No action is required. The Alinity s Anti-HCV II assay is not calibrated and run on the same processing lane as the Alinity s HIV Ag/Ab Combo assay. - Maintain the current assay configuration and ensure the Alinity s HIV Ag/Ab Combo assay is not run on the same processing lane as the Alinity s Anti-HCV II assay. The Alinity s Anti-HCV II assay and the Alinity s HIV Ag/Ab Combo assay are calibrated and run on the same processing lane. - Contact your local area customer service representative to assess the configuration and uninstall/reinstall the assays to run on separate processing lanes or instruments. Please review this letter with your Medical Director or Laboratory Management and follow your laboratory protocol regarding the need for reviewing previously reported Alinity s HIV Ag/Ab Combo assay test results while operating on Alinity s System SW version 2.8.0. If you have forwarded the product listed above to other laboratories, please inform them of this Product Correction and provide to them a copy of this letter. Please complete and return the Customer Re
- Initiated
- 2022-02-03
- Root cause
- Under Investigation by firm
- Distribution
- Worldwide distribution: US (nationwide) including states of: AL, CA, GA, IL, IN, MN, MO, NC, OK, PA, RI, SC, TN, TX, WA, WI, MD and countries (OUS) including of: Australia, Austria, Bahrain, Belgium, Brazil, china, Colombia, Croatia, Cyprus, Czech Republic, Egypt, Germany, Greece, Hong Kong, Hungary, Iran, Ireland, Israel, Italy, Jordan Kuwait and Mexico.
- Recall number
- Z-0749-2022
- Recall status
- Open, Classified
- CDRH record ID
- 192038
- FDA record created
- 2022-03-11
- Recall event number
- 89604